Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Gets CHMP Positive Opinion for Vaxneuvance Vaccine

10/15/2021 | 06:13am EST

By Colin Kellaher

Merck & Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its Vaxneuvance 15-valent pneumococcal vaccine in adults.

The Kenilworth, N.J., drugmaker said the recommendation covers Vaxneuvance for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.

The European Commission, which generally follows the CHMP's advice, will now review the recommendations, with decisions expected by the end of the year.

The U.S. Food and Drug Administration earlier this year approved Vaxneuvance for adults.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-15-21 0813ET

All news about MERCK & CO., INC.
12/03FDA Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Treatment for Adult and Pedi..
BU
12/03Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19
DJ
12/03Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupira..
AQ
12/03Canada Signs Deal for 1 Mln Doses of Pfizer Covid Antiviral and 500K Merck's Covid Pill
MT
12/03Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
12/03Bristol-Myers Squibb's Supplemental Biologics License Application for Drug Co-Developed..
MT
12/03KYODO NEWS DIGEST : Dec. 3, 2021 -3-
AQ
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/03Nikkei 225 Gains 1% on Merck Covid-19 Drug Application
MT
12/03U.S. pharma Merck unit seeks Japan's approval of oral COVID drug
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 572 M - -
Net income 2021 12 378 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 15,1x
Yield 2021 3,54%
Capitalization 185 B 185 B -
EV / Sales 2021 4,24x
EV / Sales 2022 3,55x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,34 $
Average target price 95,25 $
Spread / Average Target 29,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.34%185 253
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641